Masanori Onda, M.D., Ph.D.
Dr. Onda is focusing on the pre-clinical development of recombinant immunotoxins (RITs) as new immunotherapy reagents. RITs are genetically modified forms of Pseudomonas exotoxin A that are targeted to cancer cells by the Fv portion of antibodies. These RITs are now in clinical trials and have produced many complete remissions in cancer.
As a staff scientist, Dr. Onda uses protein engineering to make these proteins more useful in patients by decreasing their immunogenicity so more treatment cycles can be given before antibodies develop in the patients. New RITs were designed by identifying and silencing the major B cell epitopes. These new RITs are being developed for clinical trials.
New Approach to Cancer Therapy: Recombinant Immunotoxins - Reducing the immunogenicity of protein therapeutics - Reducing the immunogenicity of PE38-based immunotoxins - Identification of human B lymphocyte epitopes
New Target for Mesothelioma and Gynecological Malignancies: Mesothelin - Soluble mesothelin is a useful biomarker for mesothelioma - New antibody for mesothelin and MPF
Investigating New Molecular Targets for Immunotoxin (CAPC, PATE, etc.) New target for Osteosarcoma and Neuroblastoma: - 8H9 immunotoxin New Target for Lymphoma: - CD30 immunotoxin - CD30 antibody, which does not bind shedding epitopes
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.Proc. Natl. Acad. Sci. U.S.A.. 108: 5742-7, 2011. [ Journal Article ]
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.J. Immunol.. 177: 8822-34, 2006. [ Journal Article ]
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.Clin. Cancer Res.. 12: 4225-31, 2006. [ Journal Article ]
- J. Immunol.. 193: 48-55, 2014. [ Journal Article ]
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.Proc. Natl. Acad. Sci. U.S.A.. 109: 11782-7, 2012. [ Journal Article ]
Dr. Onda is staff scientist in the Laboratory Molecular Biology, Center for Cancer Research. He obtained his M.D. in 1989. He obtained his Ph.D. from the University of Tokyo in 1997. He received medical training (orthopedic surgery) at the University of Tokyo, Hitachi General Hospital, and Mitsui Memorial Hospital. He received research training at the Institute of Medical Science, University of Tokyo, and at NIH.